-Product revenues of $1.54 billion, a 62%
increase compared to Q3 2019-
-Company raises revenue guidance; now expects
2020 product revenues of $6.0 to $6.2 billion-
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today
reported consolidated financial results for the third quarter ended
September 30, 2020 and revised upward its full-year 2020 financial
guidance for product revenues.
"This has been another very strong quarter for Vertex with
execution across our CF business and continued earnings and revenue
growth," said Reshma Kewalramani, M.D., Chief Executive Officer and
President of Vertex. "We are pleased with our progress toward
treating all people with cystic fibrosis highlighted by several
recent milestones: the early approval and encouraging start of the
launch of KAFTRIO in the EU, positive TRIKAFTA data in children
ages 6-11, and continued expansion of our medicines' labels as with
our recent approval of KALYDECO for infants as young as 4 months of
age."
"As we extend our leadership in CF, we are also advancing a
broad pipeline of innovative therapies," continued Dr. Kewalramani.
"Our R&D strategy contemplates the high-risk nature of drug
development and therefore includes a portfolio approach to each of
our disease areas of interest. In AATD, while disappointed by the
VX-814 outcome, we look forward to the VX-864 Phase 2
proof-of-concept data in the first half of 2021. Our pipeline spans
multiple diseases, and multiple important clinical readouts are
expected from now through the end of 2021, each of which we expect
will hold transformative potential for patients and further growth
for Vertex."
Third-Quarter 2020 Financial
Highlights
Three Months Ended September
30,
%
2020
2019
Change
(in millions, except per share
amounts)
Product revenues, net
$
1,536
$
950
62%
TRIKAFTA/KAFTRIO
$
960
$
—
SYMDEKO/SYMKEVI
$
156
$
404
ORKAMBI
$
226
$
297
KALYDECO
$
194
$
249
GAAP Operating income
$
672
$
99
577%
Non-GAAP Operating income
$
854
$
403
112%
GAAP Net income
$
667
$
58
1,060%
Non-GAAP Net income
$
697
$
322
117%
GAAP Net income per share -
diluted
$
2.53
$
0.22
1,050%
Non-GAAP Net income per share -
diluted
$
2.64
$
1.23
115%
Product revenues increased 62% compared to the third
quarter of 2019, primarily driven by the uptake of TRIKAFTA in the
U.S. and the uptake of our medicines outside the U.S. following the
completion of several significant reimbursement agreements.
GAAP and non-GAAP net income increased compared to the
third quarter of 2019, largely driven by strong growth in total
product revenues.
Cash, cash equivalents and marketable securities as of
September 30, 2020 were $6.2 billion, an increase of approximately
$2.3 billion compared to $3.8 billion as of December 31, 2019
driven by strong revenue and profitability.
Third-Quarter 2020
Expenses
Three Months Ended September
30,
2020
2019
(in millions)
Combined GAAP R&D and SG&A
expenses
$
678
$
716
Combined Non-GAAP R&D and SG&A
expenses
$
497
$
416
GAAP R&D expense
$
493
$
556
Non-GAAP R&D expense
$
350
$
290
GAAP SG&A expense
$
185
$
160
Non-GAAP SG&A expense
$
147
$
127
GAAP income taxes
$
78
$
13
Non-GAAP income taxes
$
155
$
84
GAAP effective tax rate
11
%
19
%
Non-GAAP effective tax rate
18
%
21
%
Combined GAAP R&D and SG&A expenses decreased
compared to the third quarter of 2019 due to a decrease in
collaboration payments.
Combined Non-GAAP R&D and SG&A expenses increased
compared to the third quarter of 2019, primarily due to the
incremental investment to support the global use of Vertex's
medicines and the expansion of Vertex's pipeline in CF and other
disease areas.
GAAP and Non-GAAP income taxes increased compared to the
third quarter of 2019 primarily due to Vertex's increased operating
income. Refer to the "Supplemental Income Tax Information" section
for discussion of the cash versus non-cash components of Vertex's
provision for income taxes.
Full-Year 2020 Financial
Guidance
Vertex today revised upward its guidance for full-year 2020
product revenues. The company also adjusted its expectation for
combined GAAP R&D and SG&A expenses and non-GAAP effective
tax rate. Vertex's guidance is summarized below:
Current FY 2020
Previous FY 2020
TOTAL product revenues
$6.0 to 6.2 billion
$5.7 to 5.9 billion
Combined GAAP R&D and SG&A
expenses (1)
$2.5 to 2.6 billion
$2.4 to 2.55 billion
Combined Non-GAAP R&D and SG&A
expenses
Unchanged
$1.95 to 2.0 billion
Non-GAAP effective tax rate (1)
20% to 21%
21% to 22%
Key Business Highlights:
Cystic Fibrosis (CF) R&D
pipeline:
Vertex expects to increase the number of CF patients eligible to
take our medicines and thereby continue to grow our CF business.
Important progress has been made in supporting the extension of the
eligible patient population and expansion to additional geographies
and age groups.
TRIKAFTA/KAFTRIO (elexacaftor, tezacaftor and
ivacaftor)
- The European Commission granted marketing authorization for
KAFTRIO to treat people with CF ages 12 years and older with one
F508del mutation and one minimal function mutation or two F508del
mutations.
- The European Medicines Agency (EMA) validated a Type II
Variation Marketing Authorization Application (MAA) for KAFTRIO
that will support future indication expansion of the EU label to
people with CF who have one copy of the F508del mutation.
- Vertex reported positive Phase 3 data for the
elexacaftor/tezacaftor/ivacaftor triple combination in children
with CF ages 6-11 who have either two copies of the F508del
mutation or one copy of the F508del mutation and one minimal
function mutation. Vertex expects to file a supplemental New Drug
Application (sNDA) with the U.S. Food and Drug Administration (FDA)
in the fourth quarter of 2020.
- The FDA accepted three sNDAs for TRIKAFTA, SYMDEKO and
KALYDECO. These regulatory submissions are intended to expand the
labels of these drugs to include additional people with CF who have
rare CFTR mutations.
- Vertex is initiating a Phase 3 study for the
elexacaftor/tezacaftor/ivacaftor triple combination in children
with CF ages 2-5 who have either two copies of the F508del mutation
or one copy of the F508del mutation and one minimal function
mutation.
SYMDEKO/SYMKEVI (tezacaftor and ivacaftor)
- Vertex announced that the EMA's Committee for Medicinal
Products for Human Use (CHMP) adopted a positive opinion for the
label extension of SYMKEVI for the treatment of children with CF
ages 6-11 with two F508del mutations or one F508del mutation and
certain residual function mutations.
KALYDECO (ivacaftor)
- The FDA approved KALYDECO for use in infants with CF ages four
months to less than six months old who have at least one mutation
that is responsive to KALYDECO.
- Vertex announced that the EMA's CHMP adopted a positive opinion
for the label extension of KALYDECO for the treatment of infants
with CF ages 4 months to less than 6 months who have at least one
mutation that is responsive to KALYDECO.
Genetic therapies
- Vertex and Moderna established a new collaboration aimed at the
discovery and development of lipid nanoparticles (LNPs) and mRNAs
that can deliver gene-editing therapies to cells in the lung for
the treatment of CF.
R&D pipeline outside of
CF:
Vertex continues to progress a broad pipeline of potentially
transformative small molecule, cell and genetic therapies aimed at
serious diseases. Recent and anticipated progress for key pipeline
programs is noted below:
Beta Thalassemia and Sickle Cell Disease:
- Vertex and its partner CRISPR Therapeutics are evaluating the
use of an ex-vivo CRISPR gene-edited therapy for the treatment of
transfusion-dependent beta-thalassemia (TDT) and sickle cell
disease (SCD). This approach aims to edit a person’s hematopoietic
stem cells to produce fetal hemoglobin in red blood cells, which
has the potential to reduce or eliminate symptoms associated with
disease.
- Vertex and CRISPR Therapeutics previously announced that, as of
June, seven patients had been dosed across its two Phase 1/2
studies of the investigational CRISPR/Cas9 gene-editing therapy
CTX001 and presented data at the European Hematology Association
Congress from two TDT patients and one SCD patient. Additional
patients have been enrolled and dosed in both TDT and SCD studies
and the company expects to report clinical data from more patients
treated with CTX001 in addition to data from patients with longer
follow-up in the fourth quarter.
- The EMA granted Priority Medicines (PRIME) designation to
CTX001 for the treatment of severe SCD. CTX001 has also been
granted Regenerative Medicine Advanced Therapy (RMAT), Fast Track,
Orphan Drug, and Rare Pediatric Disease designations from the FDA
and Orphan Drug Designation from the European Commission for both
TDT and SCD.
Alpha-1 Antitrypsin (AAT) Deficiency:
- Vertex is evaluating multiple compounds with the potential to
correct the misfolding of Z-AAT protein in the liver, in order to
increase the levels of functional AAT in the blood. Misfolded Z-AAT
protein is the root cause of AAT deficiency.
- Enrollment is ongoing in a Phase 2 proof-of-concept study for
the Z-AAT corrector, VX-864. Data from this study is expected in
the first half of 2021.
- In October, Vertex discontinued development of VX-814 based on
the safety and pharmacokinetic profile of VX-814 observed to date
in the Phase 2 clinical study.
APOL1-mediated Kidney Diseases:
- Vertex is evaluating the potential for inhibitors of APOL1
function to reduce proteinuria in people with serious kidney
diseases, including focal segmental glomerulosclerosis (FSGS).
- Enrollment is ongoing in a Phase 2 proof-of-concept study
designed to evaluate the reduction in proteinuria in people with
APOL1-mediated FSGS after treatment with VX-147. Data from this
study is expected in 2021.
Type 1 Diabetes (T1D):
- Vertex is developing a cell therapy designed to replace
insulin-producing islet cells in people with T1D. Two opportunities
exist for the transplant of these functional islets into patients:
1) transplantation of islet cells alone, using immunosuppression to
protect the implanted cells and 2) implantation of the islet cells
inside a novel immunoprotective device.
- Vertex has completed the required enabling nonclinical studies
and manufacturing work to support the submission of an
Investigational New Drug (IND) application to the U.S. FDA for the
islet cells alone program in the fourth quarter of 2020.
Non-GAAP Financial
Measures
In this press release, Vertex's financial results and financial
guidance are provided in accordance with accounting principles
generally accepted in the United States (GAAP) and using certain
non-GAAP financial measures. In particular, non-GAAP financial
results and guidance exclude from Vertex's pre-tax income (i)
stock-based compensation expense, (ii) revenues and expenses
related to collaboration agreements, (iii) gains or losses related
to the fair value of the company's strategic investments, (iv)
increases or decreases in the fair value of contingent
consideration, (v) acquisition-related costs and (vi) other
adjustments. The company's non-GAAP financial results also exclude
from its provision for income taxes the estimated tax impact
related to its non-GAAP adjustments to pre-tax income described
above and certain discrete items. These results should not be
viewed as a substitute for the company’s GAAP results and are
provided as a complement to results provided in accordance with
GAAP. Management believes these non-GAAP financial measures help
indicate underlying trends in the company's business, are important
in comparing current results with prior period results and provide
additional information regarding the company's financial position
that the company believes is helpful to an understanding of its
ongoing business. Management also uses these non-GAAP financial
measures to establish budgets and operational goals that are
communicated internally and externally, to manage the company's
business and to evaluate its performance. The company adjusts,
where appropriate, for both revenues and expenses in order to
reflect the company's operations. The company’s calculation of
non-GAAP financial measures likely differs from the calculations
used by other companies. A reconciliation of the GAAP financial
results to non-GAAP financial results is included in the attached
financial information.
The company provides guidance regarding combined R&D and
SG&A expenses and effective tax rate on a non-GAAP basis. The
guidance regarding combined GAAP R&D and SG&A expenses does
not include estimates associated with any potential future business
development activities. The company does not provide
forward-looking reconciliations of these measures to the most
directly comparable GAAP financial measures because it is unable,
without unreasonable efforts, to calculate these GAAP measures with
reasonable certainty.
Vertex Pharmaceuticals
Incorporated
Third-Quarter Results
Consolidated Statements of
Operations
(in thousands, except per share
amounts)
(unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2020
2019
2020
2019
Revenues:
Product revenues, net
$
1,536,271
$
949,828
$
4,575,863
$
2,747,461
Collaboration and royalty revenues
2,000
—
2,000
2,095
Total revenues
1,538,271
949,828
4,577,863
2,749,556
Costs and expenses:
Cost of sales
186,182
131,914
533,199
362,746
Research and development expenses
493,497
555,948
1,362,953
1,274,529
Sales, general and administrative
expenses
184,551
159,674
558,613
463,221
Change in fair value of contingent
consideration
1,800
2,959
12,600
2,959
Total costs and expenses
866,030
850,495
2,467,365
2,103,455
Income from operations
672,241
99,333
2,110,498
646,101
Interest income
3,100
17,628
19,919
51,319
Interest expense
(13,856)
(14,548)
(41,863)
(44,253)
Other income (expense), net (2)
84,386
(31,747)
139,621
64,802
Income before provision for income
taxes
745,871
70,666
2,228,175
717,969
Provision for income taxes
78,437
13,148
120,718
124,393
Net income
$
667,434
$
57,518
$
2,107,457
$
593,576
Net income per common share:
Basic
$
2.56
$
0.22
$
8.10
$
2.32
Diluted
$
2.53
$
0.22
$
7.98
$
2.28
Shares used in per share calculations:
Basic
260,392
256,946
260,313
256,289
Diluted
264,079
260,473
264,031
260,182
Reconciliation of GAAP to
Non-GAAP Net Income
Third-Quarter Results
(in thousands, except per share
amounts)
(unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2020
2019
2020
2019
GAAP net income
$
667,434
$
57,518
$
2,107,457
$
593,576
Stock-based compensation expense
99,539
85,420
332,434
268,898
(Increase) decrease in fair value of
strategic investments (2)
(75,750)
31,216
(140,866)
(68,862)
Increase in fair value of contingent
consideration (3)
1,800
2,959
12,600
2,959
Collaborative revenues and expenses
(4)
78,050
203,777
141,300
262,286
Acquisition-related costs (5)
2,523
11,459
7,862
12,690
Total non-GAAP adjustments to pre-tax
income
106,162
334,831
353,330
477,971
Tax adjustments (6)
(76,250)
(70,849)
(402,183)
(126,951)
Non-GAAP net income
$
697,346
$
321,500
$
2,058,604
$
944,596
Net income per diluted common share:
GAAP
$
2.53
$
0.22
$
7.98
$
2.28
Non-GAAP
$
2.64
$
1.23
$
7.80
$
3.63
Shares used in diluted per share
calculations:
GAAP and Non-GAAP
264,079
260,473
264,031
260,182
Reconciliation of GAAP to
Non-GAAP Revenues and Expenses
Third-Quarter Results
(in thousands)
(unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2020
2019
2020
2019
GAAP total revenues
$
1,538,271
$
949,828
$
4,577,863
$
2,749,556
Collaborative revenues
(2,000)
—
(2,000)
(158)
Non-GAAP total revenues
$
1,536,271
$
949,828
$
4,575,863
$
2,749,398
Three Months Ended
September 30,
Nine Months Ended
September 30,
2020
2019
2020
2019
GAAP cost of sales
$
186,182
$
131,914
$
533,199
$
362,746
Stock-based compensation expense
(1,250)
(1,337)
(3,998)
(4,178)
Non-GAAP cost of sales
$
184,932
$
130,577
$
529,201
$
358,568
GAAP research and development
expenses
$
493,497
$
555,948
$
1,362,953
$
1,274,529
Stock-based compensation expense
(60,770)
(52,504)
(203,732)
(167,851)
Collaborative expenses (4)
(80,050)
(203,777)
(143,300)
(262,444)
Acquisition-related costs (5)
(2,523)
(10,122)
(7,409)
(10,122)
Non-GAAP research and development
expenses
$
350,154
$
289,545
$
1,008,512
$
834,112
GAAP sales, general and administrative
expenses
$
184,551
$
159,674
$
558,613
$
463,221
Stock-based compensation expense
(37,519)
(31,579)
(124,704)
(96,869)
Acquisition-related costs (5)
—
(1,337)
(453)
(2,568)
Non-GAAP sales, general and
administrative expenses
$
147,032
$
126,758
$
433,456
$
363,784
Combined non-GAAP R&D and SG&A
expenses
$
497,186
$
416,303
$
1,441,968
$
1,197,896
Three Months Ended
September 30,
Nine Months Ended
September 30,
2020
2019
2020
2019
GAAP other income (expense),
net
$
84,386
$
(31,747)
$
139,621
$
64,802
(Increase) decrease in fair value of
strategic investments (2)
(75,750)
31,216
(140,866)
(68,862)
Non-GAAP other income (expense),
net
$
8,636
$
(531)
$
(1,245)
$
(4,060)
GAAP provision for income taxes
$
78,437
$
13,148
$
120,718
$
124,393
Tax adjustments (6)
76,250
70,849
402,183
126,951
Non-GAAP provision for income taxes
(7)
$
154,687
$
83,997
$
522,901
$
251,344
Condensed Consolidated Balance
Sheets
(in thousands)
(unaudited)
September 30, 2020
December 31, 2019
Assets
Cash, cash equivalents and marketable
securities
$
6,151,058
$
3,808,294
Accounts receivable, net
791,917
633,518
Inventories
245,460
167,502
Property and equipment, net
920,913
745,080
Goodwill and intangible assets
1,402,158
1,402,158
Deferred tax assets
1,147,816
1,190,815
Other assets
642,311
371,098
Total assets
$
11,301,633
$
8,318,465
Liabilities and Shareholders'
Equity
Accounts payable and accrued expenses
$
1,811,485
$
1,204,522
Finance lease liabilities
587,772
577,371
Contingent consideration
189,100
176,500
Other liabilities
579,803
274,828
Shareholders' equity
8,133,473
6,085,244
Total liabilities and shareholders'
equity
$
11,301,633
$
8,318,465
Common shares outstanding
260,174
258,993
Supplemental Income Tax
Information
(in thousands, except
percentages)
(unaudited)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2020
2019
2020
2019
Components of provision for income
taxes related to:
Cash paid or accrued for income taxes
$
(2,249)
$
12,961
$
45,347
$
22,953
Benefits from income taxes due to discrete
tax items (5)
(60,244)
—
(297,599)
—
Provision for income taxes offset by net
operating losses and credits (6)
140,930
187
372,970
101,440
GAAP provision for income taxes
(7)
$
78,437
$
13,148
$
120,718
$
124,393
Cash paid or accrued for income taxes
$
(2,249)
$
12,961
$
45,347
$
22,953
Adjustments to pre-tax income
16,006
70,849
104,584
126,951
Provision for income taxes offset by net
operating losses and credits (6)
140,930
187
372,970
101,440
Non-GAAP provision for income taxes
(7)
$
154,687
$
83,997
$
522,901
$
251,344
Effective tax rate
reconciliation:
GAAP effective tax rate
11
%
19
%
5
%
17
%
Impact of GAAP to Non-GAAP adjustments
7
%
2
%
15
%
4
%
Non-GAAP effective tax rate
18
%
21
%
20
%
21
%
Notes and Explanations
1: The company's increased combined GAAP R&D and
SG&A expense guidance reflects the effect of a new
collaboration agreement in the third quarter of 2020. The company's
adjusted non-GAAP effective tax rate guidance includes a change in
the utilization of certain tax assets.
2: "Other income (expense), net" includes gains and
losses related to changes in the fair value of the company's
strategic investments.
3: During the three and nine months ended September 30,
2020 and 2019, the increase in the fair value of contingent
consideration relates to potential payments to Exonics' former
equity holders.
4: "Collaborative revenues and expenses" in the three and
nine months ended September 30, 2020 and 2019 primarily related to
collaborative upfront and milestone payments.
5: "Acquisition-related costs" in the three and nine
months ended September 30, 2020 and 2019 related to costs
associated with the company's acquisitions of Semma and
Exonics.
6: In the three and nine months ended September 30, 2020
and 2019, "Tax adjustments" primarily related to the estimated
income taxes related to non-GAAP adjustments to pre-tax income
including (i) stock-based compensation (including an adjustment for
excess tax benefits related to stock-based compensation), (ii)
increases or decreases in the fair value of the company's strategic
investments and (iii) collaborative payments. In the three and nine
months ended September 30, 2020, "Tax adjustments" also included
non-recurring discrete benefits to the company's provision for
income taxes of approximately $60.2 million and $297.6 million,
respectively, that the company excluded from its Non-GAAP
measures.
7: The company records a provision for income taxes on
its pre-tax income using an effective tax rate approximating
statutory rates. Since the company released its valuation allowance
on the majority of its net operating losses and other deferred tax
assets as of December 31, 2018, its tax provision has included a
significant non-cash charge due to the company's ability to offset
its pre-tax income against previously benefited net operating
losses and credits. As of December 31, 2019, the company's federal
net operating losses and credits that were available to offset
future pre-tax income were approximately $3.5 billion. The company
expects to utilize its remaining federal net operating losses in
2020. As a result, a larger portion of the company’s tax provision
will represent a cash expense in future periods, subject to
continued utilization of certain tax credits.
About Vertex
Vertex is a global biotechnology company that invests in
scientific innovation to create transformative medicines for people
with serious diseases. The company has multiple approved medicines
that treat the underlying cause of cystic fibrosis (CF) — a rare,
life-threatening genetic disease — and has several ongoing clinical
and research programs in CF. Beyond CF, Vertex has a robust
pipeline of investigational small molecule medicines in other
serious diseases where it has deep insight into causal human
biology, including pain, alpha-1 antitrypsin deficiency and
APOL1-mediated kidney diseases. In addition, Vertex has a rapidly
expanding pipeline of genetic and cell therapies for diseases such
as sickle cell disease, beta thalassemia, Duchenne muscular
dystrophy and type 1 diabetes mellitus.
Founded in 1989 in Cambridge, Mass., Vertex's global
headquarters is now located in Boston's Innovation District and its
international headquarters is in London. Additionally, the company
has research and development sites and commercial offices in North
America, Europe, Australia and Latin America. Vertex is
consistently recognized as one of the industry's top places to
work, including 11 consecutive years on Science magazine's Top
Employers list and a best place to work for LGBTQ equality by the
Human Rights Campaign. For company updates and to learn more about
Vertex's history of innovation, visit www.vrtx.com or follow us on
Facebook, Twitter, LinkedIn, YouTube and Instagram.
Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995,
including, without limitation, Dr. Kewalramani's statements in this
press release, the information provided regarding future financial
performance, the section captioned "Full-Year 2020 Financial
Guidance" and statements regarding (i) regulatory filings and data
submissions, (ii) anticipated future label expansions, (iii) the
expectations, development plans and anticipated timelines for the
company's medicines, drug candidates and pipeline programs,
including collaborations with third parties, and (iv) expectations
for the collaborations with Moderna. While Vertex believes the
forward-looking statements contained in this press release are
accurate, these forward-looking statements represent the company's
beliefs only as of the date of this press release and there are a
number of risks and uncertainties that could cause actual events or
results to differ materially from those expressed or implied by
such forward-looking statements. Those risks and uncertainties
include, among other things, that the company's expectations
regarding its 2020 product revenues, expenses and effective tax
rates may be incorrect (including because one or more of the
company's assumptions underlying its expectations may not be
realized), that COVID-19 may have different or more significant
impacts on the company's business or operations than the company
currently expects, that data from the company's development
programs may not support registration or further development of its
potential medicines in a timely manner, or at all, due to safety,
efficacy or other reasons, and other risks listed under Risk
Factors in Vertex's annual report and subsequent quarterly reports
filed with the Securities and Exchange Commission and available
through the company's website at www.vrtx.com. Vertex disclaims any
obligation to update the information contained in this press
release as new information becomes available.
Conference Call and
Webcast
The company will host a conference call and webcast today at
4:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.)
or +1 (720) 545-0001 (International). The conference call will be
webcast live and a link to the webcast can be accessed through
Vertex's website at www.vrtx.com in the "Investors" section under
"Events and Presentations." To ensure a timely connection, it is
recommended that users register at least 15 minutes prior to the
scheduled webcast. An archived webcast will be available on the
company's website.
(VRTX-E)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201029006132/en/
Vertex Contacts: Investors: Michael Partridge,
617-341-6108 or Zach Barber, 617-341-6470 or Brenda Eustace,
617-341-6187
Media: 617-341-6992 mediainfo@vrtx.com
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Apr 2023 to Apr 2024